Research programme: liver disorder therapeutics - Repair Biotechnologies
Latest Information Update: 29 May 2026
At a glance
- Originator Repair Biotechnologies
- Class Hepatoprotectants; Proteins
- Mechanism of Action
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease
Most Recent Events
- 29 May 2026 Preclinical trials in Non-alcoholic fatty liver disease in USA (unspecified route) (Repair Biotechnologies pipeline, May 2026)
- 28 Apr 2025 No recent reports of development identified for research development in Liver-disorders in USA
- 09 Mar 2021 Early research in Liver disorders in USA (unspecified route) prior to March 2021 (Repair Biotechnologies pipeline, March 2021)